- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 963KB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 353KB)
Ravulizumab – November 2024
Ravulizumab; Solution concentrate for I.V. infusion 300 mg in 3 mL, Solution concentrate for I.V. infusion 1,100 mg in 11 mL; Ultomiris®
Last updated
30 May 2025